Aurobindo Pharma Receives FDA Form 483 with Procedural Observations at Telangana API Facility

Aurobindo Pharma has announced the completion of a US FDA inspection at Unit-I of Apitoria Pharma Private Limited, its API manufacturing facility in Borpatla, Telangana, conducted from August 21 to 29. The inspection concluded with the issuance of a Form 483 listing five procedural observations, with no data integrity issues identified. The company clarified that the observations are not critical and affirmed it will respond to the FDA within the stipulated time, reiterating its commitment to global quality standards. Importantly, Aurobindo stated there is no impact on its financials or operations, indicating no immediate risk to production or product approvals. In a separate update, the company extended the deadline for the internal restructuring of CuraTeQ Biologics s.r.o., with the share transfer to Curateq Biologics B.V. now expected by September 30, delayed from August 31 due to administrative delays in the Netherlands. While regulatory scrutiny remains ongoing, Aurobindo’s prompt disclosures and compliance focus reflect its efforts to maintain trust and operational stability in the competitive global generics market.